True, I've seen a mixture of numbers reported, but I believe it is important to compare between cell lines. With what I think is considered an authoritative line, that is the Calu-3 cell line, Brilacidin is not only less cytotoxic, but also a more effective antiviral.

At least use equivalent cell lines please.

Literature numbers below.

Brilacidin:
426 (CC50 = 241 µM/IC50 = 0.565 µM), Calu-3 Cells [1]

Rem:
38 (CC50 = 50 µM/IC50 = 1.3 µM), Calu-3 Cells [2]


[1] Bakovic, A.; Risner, K.;
Bhalla, N.; Alem, F.; Chang, T.L.;
Weston, W.K.; Harness, J.A.;
Narayanan, A. Brilacidin
Demonstrates Inhibition of
SARS-CoV-2 in Cell Culture. Viruses
2021, 13, 271. https://doi.org/
10.3390/v13020271

[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7436731/#!po=47.7778

Yeah, companies make nothing burgers all the time, especially Big Pharma. Great point RDunn, wow you are very smart about patents, tell us more.

IPIX up 200% for the year, I'm thinking up 1000% to 10000% next year.

Great reason to be here, just saying it's not the only reason to be here. Cheers.

Study it. I've been studying it since 2011, there have been some struggles, but there have been some moments of brilliance! The acquisition of Brilacidin changed this company. I believe it will provided a standalone defining platform, but also the basis of financial security to enable the development of Kevetrin, the p53 Guardian Angel Genome enabling small molecule, that first made IPIX (then Cellceutix CTIX) such a potential pharmaceutical powerhouse.

Merry Christmas and Happy Holidays to all you fellow investors, 2021 is looking pretty darn great!

The FDA defines US trajectory, not all trajectories. I'd wager the IPIX Ireland subsidiary has strategic value beyond what many of us can understand or predict.

From latest 10q:
The subsidiary will serve as a key hub for strategic collaboration with European companies and medical communities in addition to providing cost-saving efficiencies and flexibility with respect to developing Brilacidin under European Medicines Agency standards.

IPIX up over 200% for the year and every indication suggests it will only climb more as trial analyses and results flood in early next year.

IPIX has never had a trial halted, eat your heart out BP.

No offense intended, but I am amused by your perception that a modern education corrupted a social construct built on free will. If you wanted your children to live in the 50's, why did you pay for them to be educated?

Have any of you received your free Brilacidin sample yet? I haven't received mine. Can't figure out what the hell is going on. Is it my delivery person, maybe they stole it? Leo never said he didn't ship it already, so where is it? I'm getting worried I might never get my free sample. I'm really really worried - I might post every day from now on about it until I finally receive it.

I see, it was an attempt at a deragatory twist on the original metaphor by using two phrases that have no contextual correlation to support simile. I'm not surprised at the attempt or at the lack of contextual comprehension.

You should research the term "one trick pony", obviously you are confused with the metaphor being used. Your research should clear it up.

They don't ride ponies, they just beat dead ones.

IPIX has never been a one trick pony. The pony named Brilacidin can do many tricks. The pony named Kevetrin can do many tricks, although they are primarily cancer-related tricks, very valuable gaurdian angle genomic tricks. There was also a pony named Prurisol, its trick didn't impress as much as hoped and so Leo stopped training and showing that pony to people, not even stock message board poster people who moan about not seeing that pony anymore and for some reason think Leo should waste time explaining why that pony's trick didn't impress people enough.

On to the major ponies, ponies with training and show qualities that should make lots of monies doing lots of different tricks!

looking forward to Monday! Cheers

Nope, written here, a collection of magnetic polarities stored in an order significant enough to communicate digital content interpreted by a machine language that produces alphabetic images in liquid crystal display media. It was transfered via electron migration along most likely copper conductors, but also possibly photon refraction maintained over distance by total internal reflection and periodic amplification and also electromagnetic radiation at gigahertz frequencies through air and maybe space via satellite relay. Nothing science and nature can't completely explain.

I do believe that was the source, I hope it gets re-posted.

You're mad at Leo for not releasing papers he isn't writing? You should try reading your posts before pressing Submit Post.

Like I said, I read it earlier, I hope it's true. If it is, Monday could be quite the doosie!

I read somewhere that IPIX's Brilacidin is being briefed to US government officials, that a member of Congress is watching the IND submittal process. This is great news for IPIX, I hope it is true.

I like it when you talk dirty - your illumination of MM fake-outs always translate into positive stock movement

Therapeutic will be the word of the year. Revive, relief, innovation pharma, here's to them all being great.

I'm with you both. Took a starter here earlier in the week, wish I had taken more than a starter. My "Foreign Transaction Fee" was way too high of a percentage, hahaha!!!

Haven't you been following Leo's ways for years? There won't be any shares issued to aspire - he has 6 million in cash and you know Leo. He won't issue a share until he has to, that 6 million will be used up over the next several months. Over those next several months the share price will be substantially raised with the news coming. The aspire deal is backup funding if needed and for a set dollar amount, not a set share amount. If it gets used, dilution will be a silly thing to worry about.

It took Google: "About 33,100,000 results (0.52 seconds)", you should try them, haha kidding

Very nice!

Here till $800

I've also had similar thought. Today's S-3 filing shows how remarkably uncomplicated are IPIX's books, I would think negotiators/lawyers just love the simplicity.

13g: an entity spent time likely prior to June 30th (they have 10 days to file I believe) acquiring a large enough portion of IPIX shares to necessitate a filing with the SEC - fantastic news.

S-3: note stipulations early in the filing about details subject to changes/updates, a filing that once seamed effective by the SEC, allows IPIX to raise $60 Million for corporate operations - fantastic news.

S-3 Friday after market close, let everyone who can't possibly know anything about it complain and tire themselves out over the weekend, Monday morning pre-market PR (as is typical for IPIX) to announce market moving details... Brilliant!

The last 13G position this LLC filed for in Oct 2019 shortly thereafter began the climb from $0.10 to over $1.00 recently. Maybe just a tiny bit of foreshadowing for us to ponder...

I think you have illuminated the crux of the non-existent issue At 97% reduction, even a virus with extraordinary replication speed is significantly hindered. The replication would need to be 1/(1-0.97)=33.33 fold to negate Brilacidin. I'm not sure the transport mechanisms available can even expose enough cells to support replication anywhere near that, otherwise the lethality would be crazy fast and it's not.

I'm actually amazed you would make that statement about me confirming a market reaction given the words in my post. Did you read something in my post relating to the stock price?

Let me help a tiny bit more: until someone discovers a method of freezing time and counting the precise number of remaining viable viral bodies (otherwise the number would change while you processed the sample for the counting) in each experiment, an absolute study becomes a whole new project involving multiple samples for statistical analysis. The time, the expenditure, the lack of progress when so much progress is needed by humanity. We need comparative studies to direct focus at this time.

Well, that would be the point of a comparative study. If you are upset that an absolute study was not conducted, maybe you can file a complaint with the government.

I think the answer is way more simple than the conniption you seem to be trying to create. With nothing, the viral load would increase, how do you actually think infection works? That only a single viral body causes all the destruction? Hahaha

I'm not sure if the company name change from Cellceutix to Innovation is tied at all to that nomenclature use in the patent arena, but it is quite fitting in the case of Brilacidin. Innovation Pharma Inc. has purchased the rights to a previously patented molecule and brilliantly innovated by perfecting its use in other indications. Covid is an innovation none of us saw coming, but a brilliant life-saving innovation seems it will become. Cheers.

There is a common misunderstood difference between the term invention and the term innovation. Taking an invention that has already been patented and using it in a new way or for an additional purpose would be considered an innovation using that invention. Innovations are not patentable. The fact that OM included an addition to the invention (the sachet and addition processing to enable that) was an alteration of the original invention, so can be considered a new invention and patentable. I hope I got all of that correct - that is my understanding as a patent holder and someone who has filed several applications.

The Shield of Life and The Guardian of The Genome, both owned by IPIX, a publicly traded company, far out!